Ibrance (palbociclib)
Indications for Prior Authorization
Ibrance (palbociclib)
-
For diagnosis of Breast Cancer
Indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in combination with: (1) an aromatase inhibitor as initial endocrine based therapy, or (2) fulvestrant in patients with disease progression following endocrine therapy.
Criteria
Ibrance
Prior Authorization (Initial Authorization)
Length of Approval: 12 Month(s)
- Diagnosis of breast cancer AND
- One of the following:
- Trial and failure, contraindication, or intolerance to both of the following:
- Kisqali (ribociclib)
- Verzenio (abemaciclib)
- For continuation of prior therapy
Ibrance
Prior Authorization (Reauthorization)
Length of Approval: 12 Month(s)
- Patient does not show evidence of progressive disease while on therapy
P & T Revisions
2024-03-27, 2023-08-03, 2023-06-22, 2023-06-05, 2023-04-11, 2023-03-01, 2022-05-06, 2021-09-27, 2021-05-10, 2020-04-29
References
- Ibrance Prescribing Information. Pfizer Inc. New York, NY. December 2022.
- National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Breast Cancer. v.2.2022. Available by subscription at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf Accessed April 15, 2022.
Revision History
- 2024-03-27: 2024 Annual Review
- 2023-08-03: Addition of a step through Kisqali and Verzenio
- 2023-06-22: Removed oncology specialist requirement
- 2023-06-05: Program update to remove clinical criterion and leave diagnosis and prescriber requirements.
- 2023-04-11: 2023 Annual Review.
- 2023-03-01: Updated criteria to align with FDA labeling for new indication
- 2022-05-06: 2022 Annual Review- no changes
- 2021-09-27: 2021 UM Annual Review.
- 2021-05-10: 2021 UM Annual Review.
- 2020-04-29: New tablet formulation now available, approved for the same indications as the capsule. Added tablets to existing Ibrance PA
HEALTHY LIVING